Stopping the world’s biggest killer

Cardiovascular disease is the primary source of death in the world, killing more than 20 million people every year through conditions, such as heart attack, stroke and heart failure. This World Heart Day, we join forces with people across the world to reduce the number of premature deaths and to promote new treatments and improved disease prevention.

We at Fluicell are dedicated to advancing cardiac health by providing transformative tissue engingeering solutions for research, drug development and regenerative medicine. Our Biopixlar high-resolution 3D bioprinting technology makes it possible to engineer functional cardiac tissues for use as in vitro research models or for regenerative research applications with cell level precision. Using Biopixlar, you can create everything from complex cardiac tissue sections that accurately mimics human histology to precisely engineered cardiac organoids.

To reduce the number of deaths from heart disease, we need new types of treatment, new tools to advance research, improved care and increased disease prevention. Learn more about world heart day and what you can to prevent heart disease on the World heart federation website:

Fluicell and heart disease

Fluicell’s tissue engineering technology allows us to target heart disease and cardiac safety in multiple ways. We are currently developing cardiac tissue models with applications across cardiac safety screening as well as cardiac disease modeling.

Most currently used cell-based cardiac models are either monocultures or simple mixtures, and do not account for cell type diversity, ECM composition, cell-cell interactions, and microenvironment geometry.

Our advanced cardiac models are developed to target some of the main challenges to achieve fully predictive in vitro models:

  • Ability to replicate complex microenvironment and interplay between the cell types beyond simple cardiomyocyte monoculture.
  • Ability to Replicate role for each cell type in maintaining homoestasis and restoration of function upon acute damage or toxic exposure.
  • Accurate representation of the organ tissue composition
  • Having repeatable on-demand tissues to fit into regulatory systems.

Fluicell’s cardiac research capacity also extends regenerative medicine. We are currently conducting early-stage development of multifunctional bioprinted cardiac patches for treatment of Myocardial infarction. Contact us to learn more about Fluicell’s cardiac research and development activities and capabilities.


Contact Us